Genetic Technologies (ASX:GTG) Cyclically Adjusted PS Ratio: (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Technologies Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Genetic Technologies  (ASX:GTG) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Genetic Technologies Cyclically Adjusted PS Ratio Related Terms


Genetic Technologies Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Cyclically Adjusted PS Ratio Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:GTG vs LDDD, NOTV, ATLN: Cyclically Adjusted PS Ratio Comparison

For the Diagnostics & Research subindustry, Genetic Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Technologies Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Cyclically Adjusted PS Ratio falls into.



Genetic Technologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Genetic Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Genetic Technologies's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0/*
=

Current CPI (Jun. 2024) = .

Genetic Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200912 0.000 0.000
201006 0.000 0.000
201012 0.000 0.000
201106 0.000 0.000
201112 0.000 0.000
201203 0.000 0.000
201206 0.000 0.000
201212 0.000 0.000
201303 0.000 0.000
201306 0.000 0.000
201312 0.000 0.000
201406 0.000 0.000
201412 0.000 0.000
201506 0.000 0.000
201512 0.000 0.000
201606 0.000 0.000
201612 0.000 0.000
201706 0.000 0.000
201712 0.000 0.000
201806 0.000 0.000
201812 0.000 0.000
201906 0.000 0.000
201912 0.000 0.000
202006 0.000 0.000
202009 0.000 0.000
202012 0.000 0.000
202103 0.000 0.000
202106 0.000 0.000
202109 0.000 0.000
202112 0.000 0.000
202203 0.000 0.000
202206 0.000 0.000
202209 0.000 0.000
202212 0.000 0.000
202303 0.000 0.000
202306 0.000 0.000
202309 0.000 0.000
202312 0.000 0.000
202403 0.000 0.000
202406 0.000 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.